DLA Piper advised San Diego-based ResMed, the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, in its acquisition of the Atlanta-based Brightree, a leader in business management and clinical software applications for the post-acute care industry.

The US$800 million acquisition will bolster ResMed's global leadership in connected healthcare solutions. Brightree's cloud-based software helps customers improve clinical and business performance in the post-acute care industries of home/durable medical equipment, home health, and hospice – all areas with high prevalence of sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases

On completion of the transaction, Brightree will continue to operate as a separate entity under the Brightree brand name. The company will be managed independently, with its headquarters remaining in Atlanta. ResMed expects Brightree employees, including Brightree President and CEO Dave Cormack, to continue in their current roles.

The DLA Piper team representing ResMed included corporate partner Martin Nichols, senior counsel Jeff Shohet, and associates Shehzad Huda, Terence Chen, Jennifer Consul, Amanda Fitzsimmons (all of San Diego) and Leilani Lipa (Silicon Valley). Additionally, partner Nate McKitterick (Silicon Valley) advised on insurance matters, partner Neil Balmert (San Diego) advised on tax matters and partners Jim Telfer and Mark Boxer (both of San Francisco) advised on executive compensation and benefits.